Skip to main content
. Author manuscript; available in PMC: 2016 Mar 25.
Published in final edited form as: J Nanomed Nanotechnol. 2015 Dec 27;6(6):340. doi: 10.4172/2157-7439.1000340

Figure 1.

Figure 1

ESAT-6 exacerbates granulomatous changes. Figures show representative sections of lung from each treatment or control group (Hematoxylin and Eosin, 200×) (n=3/group). No granulomas were detected in either Sham-treated controls (A) or mice treated with ESAT-6 alone (B). Granulomas are visible in mice instilled with MWCNT (C) and are more frequent in mice instilled with the combination of MWCNT + ESAT-6 (D). Analysis by a semi-quantitative scoring system indicated significant (p ≤ 0.05) elevation of granulomatous changes in mice receiving MWCNT + ESAT-6 compared to those receiving MWCNT alone (E).